2025-04-25 - Analysis Report
## Natera Inc. (NTRA) Stock Review

**0. Key Figures:**

* **Cumulative Return (NTRA):** 134.50%
* **Cumulative Return (VOO):** 77.05%
* **Return Difference (NTRA vs VOO):** 57.4%
* **Relative Divergence:** 15.8% (Indicates NTRA's performance is relatively strong compared to the historical range of its outperformance against VOO)


**1. Company Overview and Performance Comparison:**

Natera Inc. is a company focused on genetic testing and diagnostics.  Over the analyzed period, NTRA significantly outperformed the S&P 500 (VOO), exhibiting a substantially higher cumulative return.  While the relative divergence suggests strong performance, it's crucial to consider the substantial volatility reflected in the provided alpha and beta data.

**Alpha and Beta Analysis:**

The provided data shows significant volatility in both alpha and beta over the years.  High alpha values in some periods (e.g., 2017-2019, 2018-2020) indicate substantial outperformance, while negative alpha and high negative CAGR  in other periods (e.g., 2021-2023) highlight periods of significant underperformance.  The beta consistently fluctuates, reflecting sensitivity to market movements but without a clear consistent trend.  Market cap also shows significant growth and fluctuation during the period.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -6.0% | 62.4% | -0.1 | 1.2 |       |
| 2016-2018  | 29.0% | 80.1% | 0.0 | 1.9 |       |
| 2017-2019  | 159.0% | 80.1% | 1.3 | 4.5 |       |
| 2018-2020  | 530.0% | 80.1% | 0.7 | 13.4 |       |
| 2019-2021  | 355.0% | 62.9% | 0.3 | 12.6 |       |
| 2020-2022  | -119.0% | 62.9% | 0.3 | 5.4 |       |
| 2021-2023  | -482.0% | 69.9% | 1.3 | 8.5 |       |
| 2022-2024  | -75.0% | 70.6% | 1.3 | 21.4 |       |
| 2023-2025  | 83.0% | 72.8% | 0.9 | 20.9 |       |


**2. Recent Price Movement:**

* **Closing Price:** $154.48
* **5-Day Moving Average:** $147.59
* **20-Day Moving Average:** $144.61
* **60-Day Moving Average:** $153.93

The price is slightly above the 60-day moving average, suggesting a relatively stable short-term trend.  However, it's significantly above the 20-day and 5-day moving averages, indicating recent strong upward momentum. The daily price change of $3.98 represents a significant increase (2.68%) compared to the previous close.  This suggests a recent period of rapid price appreciation.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4053 (Medium Risk)
* **RSI:** 60.67 (Slightly above neutral; not overbought)
* **PPO:** 0.84 (Positive; indicates bullish momentum)
* **Recent Relative Divergence Change:** +0.1 (Short-term upward trend)
* **Expected Return:** 100.3% (This high figure needs further validation and context.  It is likely based on assumptions that should be explicitly stated).

The technical indicators suggest a moderately bullish sentiment.  The significant price increase ("change" in the provided data) supports the positive momentum.  The high expected return requires careful consideration and clarification of the underlying assumptions.


**4. Recent Earnings Analysis:**

The provided earnings data shows consistent net losses (negative EPS) over the reported quarters. Revenue has generally increased but at a slower pace in the last quarters, with a slight decrease  between Q2 2024 and Q3 2024. The company's financial health needs further scrutiny as the continued losses are concerning.

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-12 | -$0.26 | $0.44 B      |
| 2024-08-09 | -$0.30 | $0.41 B      |
| 2024-05-10 | -$0.56 | $0.37 B      |
| 2023-11-09 | -$0.95 | $0.27 B      |
| 2024-11-12 | -$0.95 | $0.27 B      |


**5. Financial Information:**

Revenue is growing, but profit margins are declining slightly, while the capital and profitability data indicates a negative return on equity (ROE) over the reported period. This suggests that the company is not currently generating profits from its equity.  Further investigation into the causes of negative ROE is necessary.


| Quarter     | Revenue | Profit Margin | Equity   | ROE      |
|-------------|---------|---------------|----------|----------|
| 2024-12-31 | $0.48B  | 62.94%        | $1.20B  | -4.50%   |
| 2024-09-30 | $0.44B  | 61.79%        | $0.88B  | -3.60%   |
| 2024-06-30 | $0.41B  | 58.83%        | $0.84B  | -4.48%   |
| 2024-03-31 | $0.37B  | 56.72%        | $0.79B  | -8.51%   |
| 2023-12-31 | $0.31B  | 51.38%        | $0.77B  | -10.20%  |


**6. Overall Analysis:**

NTRA has shown periods of exceptional growth, significantly outperforming the S&P 500. However, the data also reveals substantial volatility and periods of significant underperformance. The recent price surge is positive, but it's crucial to consider the negative EPS and ROE. The high expected return requires a thorough examination of its underlying assumptions.  Before making any investment decisions, a deeper dive into the company's financials, competitive landscape, and future prospects is essential.  The current positive momentum needs to be carefully evaluated against the companyâ€™s underlying financial performance and sustainability of this growth.  The high volatility makes this a high-risk investment.
